OrbiMed’s Clovis Oncology, Inc. CLVS Stock Holding History

OrbiMed’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-100,000	Closed	-$4.55M	–	161
2018 Q2	$4.55M	Buy	100,000 +35,000	+54%	+$1.7M	0.05%	129
2018 Q1	$3.43M	Buy	+65,000	New	+$3.79M	0.04%	124

Other funds holding CLVS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

OrbiMed's CLVS Position: Q3 2019 in Review

OrbiMed sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 1,913,234 shares — an estimated $28.4M sold.

OrbiMed first reported a position in CLVS in Q4 2014 and held it in 15 quarters. The position peaked at $197M in Q2 2017. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

OrbiMed reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
OrbiMed sold 1,913,234 Clovis Oncology, Inc. shares in Q3 2019, an estimated $28.4M.
OrbiMed first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 15 quarters.
OrbiMed's Clovis Oncology, Inc. position peaked at $197M in Q2 2017.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.